BRPI0312002B8 - composição para solubilização de paclitaxel e método de preparação da mesma - Google Patents
composição para solubilização de paclitaxel e método de preparação da mesmaInfo
- Publication number
- BRPI0312002B8 BRPI0312002B8 BRPI0312002A BRPI0312002A BRPI0312002B8 BR PI0312002 B8 BRPI0312002 B8 BR PI0312002B8 BR PI0312002 A BRPI0312002 A BR PI0312002A BR PI0312002 A BRPI0312002 A BR PI0312002A BR PI0312002 B8 BRPI0312002 B8 BR PI0312002B8
- Authority
- BR
- Brazil
- Prior art keywords
- paclitaxel
- composition
- weight
- solubilization
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"COMPOSIÇÃO PARA SOLUBILIZAÇÃO DE PACLITAXEL E MÉTODO DE PREPARAÇÃO DA MESMA". A presente invenção refere-se a uma composição de paclitaxel e aos métodos de preparação da mesma para solubilizar o paclitaxel onde a referida composição compreende 4-90% em peso de pelo menos um selecionado dos monoglicerídeos, 0,01-90% em peso de pelo menos um óleo e 0,01-20% em peso de paclitaxel. A presente invenção também refere-se a uma composição de paclitaxel incluindo emulsificantes e aos métodos de preparação da mesma para solubilizar o paclitaxel onde a referida composição compreende 4-90% em peso de pelo menos um selecionado dos monoglicerídeos, 0,01-90% em peso de pelo menos um óleo, 0,01-90% em peso de pelo menos um emulsificante e 0,01-20% em peso de paclitaxel. A composição da presente invenção é um sistema de distribuição de paclitaxel eficaz uma vez que a composição solubiliza o paclitaxel, não forma agregados depois ser dispersada em água, adsorve bem na parede intestinal, e portanto tem alta biodisponibilidade.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0042791A KR100533458B1 (ko) | 2002-07-20 | 2002-07-20 | 파클리탁셀의 가용화용 조성물 및 그의 제조 방법 |
PCT/KR2003/001427 WO2004009075A1 (en) | 2002-07-20 | 2003-07-18 | Composition for solubilization of paclitaxel and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0312002B8 true BRPI0312002B8 (pt) | 2022-10-18 |
Family
ID=36386602
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0312002A BRPI0312002B8 (pt) | 2002-07-20 | 2003-07-18 | composição para solubilização de paclitaxel e método de preparação da mesma |
BRPI0312002-3A BRPI0312002B1 (pt) | 2002-07-20 | 2003-07-18 | Composition for solubilization of paclitaxel and method of preparing the same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0312002-3A BRPI0312002B1 (pt) | 2002-07-20 | 2003-07-18 | Composition for solubilization of paclitaxel and method of preparing the same |
Country Status (12)
Country | Link |
---|---|
US (1) | US8075917B2 (pt) |
EP (1) | EP1545499B1 (pt) |
JP (1) | JP4744875B2 (pt) |
KR (1) | KR100533458B1 (pt) |
CN (1) | CN100544714C (pt) |
AU (1) | AU2003281465A1 (pt) |
BR (2) | BRPI0312002B8 (pt) |
CA (1) | CA2493336C (pt) |
HK (1) | HK1082674A1 (pt) |
RU (1) | RU2291693C2 (pt) |
WO (1) | WO2004009075A1 (pt) |
ZA (1) | ZA200409126B (pt) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7927368B2 (en) | 2002-03-25 | 2011-04-19 | Kieran Murphy Llc | Device viewable under an imaging beam |
US20030181810A1 (en) * | 2002-03-25 | 2003-09-25 | Murphy Kieran P. | Kit for image guided surgical procedures |
US9375203B2 (en) | 2002-03-25 | 2016-06-28 | Kieran Murphy Llc | Biopsy needle |
KR100533460B1 (ko) * | 2002-07-20 | 2005-12-08 | 대화제약 주식회사 | 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법 |
WO2006050246A2 (en) | 2004-11-02 | 2006-05-11 | Tel-Aviv University Future Technology Development L.P. | Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles, their manufacturing and their use for diagnostics and therapy |
EP1787645A1 (en) * | 2005-11-18 | 2007-05-23 | Institut Curie | New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway |
KR100737742B1 (ko) * | 2005-12-05 | 2007-07-10 | 대화제약 주식회사 | 파클리탁셀 조성물의 제조 방법 |
CN101006997B (zh) * | 2006-01-26 | 2011-07-20 | 董英杰 | 复方紫杉醇及衍生物多西他赛脂肪乳剂和制备方法 |
JPWO2008041553A1 (ja) | 2006-09-26 | 2010-02-04 | アステラス製薬株式会社 | タクロリムス徐放性製剤 |
CA2674039A1 (en) | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | Sustained release formulation for tacrolimus |
WO2008098415A1 (fr) * | 2007-02-14 | 2008-08-21 | Beijing Century Biocom Pharmaceutical Technology Co., Ltd. | Composition pharmaceutique contenant du taxane et son procédé de préparation et d'application |
JP5135852B2 (ja) * | 2007-03-30 | 2013-02-06 | 日油株式会社 | 可溶化用組成物 |
EP2204167A1 (en) | 2009-01-05 | 2010-07-07 | Azad Pharma AG | Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules |
CN101785757B (zh) * | 2009-01-22 | 2012-02-22 | 美迪思生物科技(北京)有限公司 | 一种紫杉醇自乳化制剂及其制备方法和用途 |
CN101926757B (zh) * | 2010-09-01 | 2013-01-02 | 北京大学 | 一种难溶性药物的液体组合物及其制备方法 |
EP2715359A4 (en) * | 2011-05-30 | 2015-01-21 | String Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE MONITORING AND DOSED ADMINISTRATION OF A THERAPEUTIC MEDICINE BY PHARMACO-KINETIC PROFILING ON PLACES OF CARE |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
ES2791604T3 (es) * | 2012-07-16 | 2020-11-05 | Ct Disease Contr & Prevention | Kits de detección de lectura directa para contaminación de superficie por fármacos antineoplásicos |
US9018246B2 (en) | 2012-09-05 | 2015-04-28 | Lp Pharmaceutical (Xiamen) Co., Ltd. | Transmucosal administration of taxanes |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
JP2017523138A (ja) | 2014-07-29 | 2017-08-17 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 経皮クリーム |
ES2524248B2 (es) * | 2014-08-01 | 2015-07-03 | Lvd Biotech S.L. | Balón liberador de paclitaxel y procedimiento de fabricación del mismo |
KR101542364B1 (ko) | 2014-10-31 | 2015-08-07 | 대화제약 주식회사 | 탁산을 포함하는 경구 투여용 약학 조성물 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
KR101612257B1 (ko) * | 2015-07-30 | 2016-04-20 | 대화제약 주식회사 | 고농도의 탁산을 포함하는 경구 투여용 약학 조성물 |
ES2895948T3 (es) * | 2015-07-30 | 2022-02-23 | Dae Hwa Pharma Co Ltd | Composición farmacéutica para administración oral que comprende taxano a alta concentración |
BR112018005200A2 (pt) | 2015-09-16 | 2018-10-09 | Dfb Soria Llc | liberação de nanopartículas de fármaco e métodos de uso dos mesmos |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2017214497A1 (en) | 2016-06-10 | 2017-12-14 | Clarity Cosmetics Inc. | Non-comedogenic hair and scalp care formulations and method for use |
CN106620717B (zh) * | 2016-12-13 | 2020-11-24 | 上海交通大学 | 一种具有逆转肿瘤多药耐药性功能的两亲性缀合物抗肿瘤纳米药及其制备方法和应用 |
KR101991661B1 (ko) * | 2017-03-02 | 2019-06-21 | 대화제약 주식회사 | 자나미비르를 포함하는 안정한 약제학적 조성물 |
WO2018159941A1 (ko) * | 2017-03-02 | 2018-09-07 | 대화제약 주식회사 | 자나미비르를 포함하는 안정한 약제학적 조성물 |
CA3056395C (en) | 2017-03-15 | 2022-06-28 | Dfb Soria, Llc | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes |
WO2018209293A2 (en) | 2017-05-11 | 2018-11-15 | The Regents Of The University Of California | Nanoscale multiple emulsions and nanoparticles |
WO2019178024A1 (en) | 2018-03-16 | 2019-09-19 | Dfb Soria, Llc | Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes |
KR20200005110A (ko) * | 2018-07-05 | 2020-01-15 | 대화제약 주식회사 | 탁산-함유 약학 조성물을 함유하는 의약품의 안정성 개선방법 |
KR102093100B1 (ko) * | 2018-07-11 | 2020-03-26 | 대화제약 주식회사 | 산화 안정성이 향상된 탁산을 포함하는 경구용 약학 조성물 |
CN109821055A (zh) * | 2019-02-01 | 2019-05-31 | 厦门大学 | 一种药物-碘油溶剂及其制备方法 |
KR20200142943A (ko) * | 2019-06-14 | 2020-12-23 | 대화제약 주식회사 | 항바이러스제를 포함하는 분말 제제 형태의 경구투여용 약학 조성물 |
KR102185475B1 (ko) | 2019-06-20 | 2020-12-02 | 대화제약 주식회사 | 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물 |
CN110302434A (zh) * | 2019-07-14 | 2019-10-08 | 大连医科大学 | 一种易于推注的碘化油栓塞剂及其制备方法 |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
CN113244254B (zh) * | 2021-03-26 | 2023-03-14 | 浙江工业大学 | 一种增强金黄霉素a水溶性的组合物及其制备与应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5618914A (en) | 1979-07-25 | 1981-02-23 | Eisai Co Ltd | Ubidecarenone composition having good absorbability |
JPH0629180B2 (ja) | 1986-06-16 | 1994-04-20 | エーザイ株式会社 | 吸収性の改良されたメナテトレノン含有組成物 |
EP0448091B1 (en) | 1990-03-23 | 1998-08-05 | The Green Cross Corporation | Pharmaceutical composition containing slightly water-soluble drug |
NZ243721A (en) | 1991-07-26 | 1994-11-25 | Smithkline Beecham Corp | Self-emulsifying microemulsion comprising water soluble drug, high hlb surfactant and a lipophilic phase containing fatty acid triglyceride and a low hlb surfactant |
DE4322826A1 (de) | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmazeutisches Präparat |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5616330A (en) * | 1994-07-19 | 1997-04-01 | Hemagen/Pfc | Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same |
EP0999838B1 (en) * | 1997-07-29 | 2002-04-03 | PHARMACIA & UPJOHN COMPANY | Self-emulsifying formulation for lipophilic compounds |
CA2294031E (en) | 1997-07-29 | 2012-04-03 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
WO1999049948A1 (en) * | 1998-04-01 | 1999-10-07 | Mattel, Inc. | Toy vehicle jumpset with crossing rise and descent paths |
US6146659A (en) | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
GB9907715D0 (en) * | 1999-04-01 | 1999-05-26 | Scherer Corp R P | Pharmaceutical compositions |
EP1189597A4 (en) | 1999-06-04 | 2008-06-18 | Pacira Pharmaceuticals Inc | COMPOSITIONS USING AN OIL CORE FOR DELAYED RELEASE HYDROPHOLE MEDICAMENTS |
IL148685A0 (en) * | 1999-09-21 | 2002-09-12 | Rtp Pharma Inc | Surface modified particulate compositions of biologically active substances |
KR20010100194A (ko) * | 2000-03-13 | 2001-11-14 | 박호군 | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 |
AU2001247739A1 (en) | 2000-03-24 | 2001-10-08 | Baker Norton Pharmaceuticals, Inc. | Uses of metal salts to stabilize taxane-based compositions |
JP3448006B2 (ja) * | 2000-03-29 | 2003-09-16 | 独立行政法人食品総合研究所 | 機能性エマルション |
DE10036871A1 (de) * | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe |
KR20020013174A (ko) * | 2000-08-11 | 2002-02-20 | 민경윤 | 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물 |
JP2004520398A (ja) | 2001-01-18 | 2004-07-08 | ファルマシア・アンド・アップジョン・カンパニー | 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物 |
US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
WO2003045357A1 (en) | 2001-11-27 | 2003-06-05 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
CN1273130C (zh) | 2001-12-20 | 2006-09-06 | 布里斯托尔-迈尔斯斯奎布公司 | 具有增大的生物利用率的口服活性紫杉烷衍生物的药物组合物 |
KR100573289B1 (ko) * | 2002-07-20 | 2006-04-24 | 대화제약 주식회사 | 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법 |
KR100533460B1 (ko) * | 2002-07-20 | 2005-12-08 | 대화제약 주식회사 | 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법 |
-
2002
- 2002-07-20 KR KR10-2002-0042791A patent/KR100533458B1/ko active IP Right Grant
-
2003
- 2003-07-18 AU AU2003281465A patent/AU2003281465A1/en not_active Abandoned
- 2003-07-18 RU RU2005104567/15A patent/RU2291693C2/ru active
- 2003-07-18 EP EP03741592A patent/EP1545499B1/en not_active Expired - Lifetime
- 2003-07-18 BR BRPI0312002A patent/BRPI0312002B8/pt active IP Right Grant
- 2003-07-18 BR BRPI0312002-3A patent/BRPI0312002B1/pt active IP Right Grant
- 2003-07-18 JP JP2004522819A patent/JP4744875B2/ja not_active Expired - Lifetime
- 2003-07-18 WO PCT/KR2003/001427 patent/WO2004009075A1/en active Application Filing
- 2003-07-18 CA CA002493336A patent/CA2493336C/en not_active Expired - Lifetime
- 2003-07-18 US US10/521,669 patent/US8075917B2/en active Active
- 2003-07-18 CN CNB038173468A patent/CN100544714C/zh not_active Expired - Lifetime
-
2004
- 2004-11-11 ZA ZA2004/09126A patent/ZA200409126B/en unknown
-
2006
- 2006-02-03 HK HK06101474.7A patent/HK1082674A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20060104999A1 (en) | 2006-05-18 |
ZA200409126B (en) | 2005-06-29 |
CA2493336A1 (en) | 2004-01-29 |
CN100544714C (zh) | 2009-09-30 |
CA2493336C (en) | 2009-11-24 |
KR100533458B1 (ko) | 2005-12-07 |
WO2004009075A1 (en) | 2004-01-29 |
HK1082674A1 (en) | 2006-06-16 |
BRPI0312002B1 (pt) | 2017-11-28 |
EP1545499B1 (en) | 2013-02-20 |
US8075917B2 (en) | 2011-12-13 |
KR20040009015A (ko) | 2004-01-31 |
EP1545499A1 (en) | 2005-06-29 |
BR0312002A (pt) | 2005-05-03 |
AU2003281465A1 (en) | 2004-02-09 |
JP4744875B2 (ja) | 2011-08-10 |
RU2291693C2 (ru) | 2007-01-20 |
RU2005104567A (ru) | 2005-07-10 |
CN1671370A (zh) | 2005-09-21 |
EP1545499A4 (en) | 2009-11-18 |
JP2005538090A (ja) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0312002B8 (pt) | composição para solubilização de paclitaxel e método de preparação da mesma | |
Pfaus | Frank A. Beach award: Homologies of animal and human sexual behaviors | |
BR0310099A (pt) | método para tratar dislipidemia ou uma doença associada com a dislipidemia | |
NO20071651L (no) | Lav olje emulsjonssammensetninger for levering av taxoider og andre uopploslige medikamenter. | |
KR950031069A (ko) | 골손실의 억제 및 혈청 콜레스테롤의 강하 방법 | |
BRPI0506461A (pt) | método implementado por computador para executar em um computador um sistema de computação de múltiplos agentes baseado no comportamento, sistema de computação de múltiplos agentes baseado no comportamento, mìdia que se pode ser lida por computador e programa de computador em uma mìdia que pode ser lida por computador | |
UY27165A1 (es) | 6,7,8,9-tetrahidro-5h-benzocicolheptenil aminas aciladas y su uso como farmacos | |
BRPI0416752B8 (pt) | composição farmacêutica, uso de um ou mais compostos, e, compostos | |
BR0307524A (pt) | Composição farmacêutica para inibidores de protease viral de hepatite c | |
CY1111471T1 (el) | Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης | |
GT200500339A (es) | Compuestos y derivados de dibencil amina | |
ATE320259T1 (de) | Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen | |
NO2016012I2 (no) | Betulin (bjørkeneverekstrakt) | |
FR2885527B1 (fr) | Composition pharmaceutique comprenant un onguent oleagineux et de la vitamine d ou ses derives a l'etat solubilise | |
Garcia et al. | The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen | |
BR0312024A (pt) | Uso de derivados de ciclotiocarbamato no tratamento de condições relacionadas com hormÈnios | |
BR112021020359A2 (pt) | Composição autoemulsificante de fármaco de polifenol de flavonoide, método de preparação da mesma, composição farmacêutica da mesma e aplicação da mesma | |
BRPI0608061A2 (pt) | método para abaixar os nìveis no sangue circulante de um lipìdio selecionado do grupo que consiste em colesterol ldl, triglicerìdios, colesterol total, e as misturas destes e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons | |
BR9912024A (pt) | Emplastros em gel contento esteróide e processo para a produção dos mesmos | |
CL2008003002A1 (es) | Composición farmacéutica inyectable intravenosa en forma de emulsión aceite en agua que comprende al toxoide larotaxel (xrp9881) o cabazitaxel (xrp6258) disuelto en lecitina, y al tensioactivo aniónico fosfatidilglicerol o acido fosfatidico; proeceidimiento para su preparacion, útil como antineoplástico. | |
KR950016735A (ko) | 터너 증후군의 억제 방법 | |
EA200200217A1 (ru) | Парентеральная цисплатиновая эмульсия | |
Madsen et al. | 4-tert-octylphenol and 17β-estradiol applied by feeding to flounder Platichthys flesus: induction of vitellogenin and accumulation in tissues | |
AR035730A1 (es) | Derivados de 2-arilamino-2,3-dihidrotiazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento | |
KR900003174A (ko) | 벤조푸로[3,2-c] 퀴놀린 화합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: DAEHWA PHARM. CO., LTD. (KR) Free format text: TRANSFERIDO DE: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 31/337; A61P 35/00 Ipc: A61K 31/337 (2011.01), A61P 35/00 (2011.01) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted | ||
B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |